CardioRenal Systems® is the developer of the only clinically validated solution for preventing Acute Kidney Injury (AKI) in common hospitalizations from cardiac surgery and interventional cardiology to ICU. Its next generation device for fluid management and AKI prevention is CE approved with growing sales throughout EMEA and was granted breakthrough designation by the FDA. AKI prevention is a major unmet medical need and a $10B+ addressable market.In the UK based KIDNEY Study, a 220-patient randomized, controlled clinical trial, RenalGuard Therapy® demonstrated a 52% reduction in AKI compared to the standard of care. In the 780K annual cardiac surgery procedures in the US & EMEA, 80% of patients are at risk, and 30% of patients go on to suffer from AKI. There is also increasing awareness of sepsis associated AKI in the ICU, where initial POC studies have shown promising results.

Imagine Bio advises global healthcare leaders and emerging startups on strategy, partnerships, and investments. Our experienced team of healthcare experts, supports leading pharma, med-tech, and healthcare provider firms to design and implement new and innovation strategies effectively. Beyond access to emerging technologies, our clients benefit from our experience designing global innovation business strategies, tailored market analyses and due diligence, advice on new and emerging value-based business models, and best practices for pilots and integration. We operate globally with clients based in the US, EU, and Israel.Imagine Bio is a division of Blue Stream Partners Ltd.

• Managed clinical stage medical diagnostics start-up developing an Alzheimer’s and ALS diagnostic blood testManaged turn-around of clinical stage biotech company developing Alzheimer’s and ALS diagnostic blood tests• Recruited by Trendlines' Misgav Incubator to turn-around failing company with strong proof-of-concept• Refocused efforts on strategic clinical and commercial partnerships for Alzheimer’s diagnostic• Secured equity financing from multiple investors and institutions• Secured multi-million-dollar in-kind support for clinical validation in globally recognized cohort of 1,000 Alzheimer’s patients• Nurtured strategic partnerships with key local and international industry leaders including Harvard’s Clinical Research Institute• Successfully renegotiated licensing agreement with Yeda (Weizmann Institute- Technology Transfer Organization)• Established relationships with global pharma and diagnostic companies towards eventual exit• NeuroQuest selected in “Top 10 Israeli Medical Advances to Watch in 2014” by Israel21C

MND Diagnostics was founded in 2004 to develop innovations in rapid diagnostic technologies. The companies pipeline included a platform for rapid POC viral and bacterial diagnosis, a blood test for liver fibrosis, and a test for the women's health field. The company sought to provide the world with an accurate, rapid and portable diagnostic platform allowing for the right treatment at the right time in a dynamic variety of locations.

• Compiled worldwide sales and profit for presentation to corporate customers ranging from analysts to CFO.• Developed a financial reporting tool to automate compilation of a previously manual report allowing for priority shift towards more personalized service of diverse clients and business needs.

• Awarded Dean Scholarship in recognition of the vision, direction, and collaboration in our teams research to improve solar cell efficiency.• Published novel organic synthesis of ruthenium-based dye molecules in European Journal of Organic Chemistry.

• Selected for National Science Foundation (NSF) sponsored research to developed scale-up process enabling industrial synthesis of cancer repressing oligosaccharide iGB3. • Successfully created critical scale-up process for industrializing enzymatic synthesis.